checkAd

    ZTS LOSS ALERT  137  0 Kommentare ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Inquire About Securities Class Action Investigation – ZTS

    WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zoetis Inc. (NYSE: ZTS) resulting from allegations that Zoetis may have issued materially misleading business information to the investing public.

    SO WHAT: If you purchased Zoetis securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Zoetis!
    Short
    171,96€
    Basispreis
    1,25
    Ask
    × 10,35
    Hebel
    Long
    144,20€
    Basispreis
    1,52
    Ask
    × 8,52
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=24154 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

    WHAT IS THIS ABOUT: On April 12, 2024, before the market opened, The Wall Street Journal released an article entitled “What Killed Their Pets? Owners Blame Meds, but Vets Aren’t Sure.” This article discussed possible side effects caused by Librela and Solensia, two drugs which are produced by Zoetis, and are respectively used to treat arthritis in dogs and cats. Further, the article stated that “[h]ealth regulators in the U.S. and Europe—which have received thousands of reports of side effects—are conducting reviews” and that “[t]he FDA received more than 3,800 reports of side effects concerning the drugs through the end of last year.”

    On this news, the price of Zoetis stock fell by $12.75 per share, or 7.83%, to close at $149.98 on April 12, 2024.

    WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

    Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

    Attorney Advertising. Prior results do not guarantee a similar outcome.


    The Zoetis Registered (A) Stock at the time of publication of the news with a fall of -0,21 % to 149,7USD on NYSE stock exchange (15. April 2024, 21:14 Uhr).

    Diskutieren Sie über die enthaltenen Werte


    Business Wire (engl.)
    0 Follower
    Autor folgen

    ZTS LOSS ALERT ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Inquire About Securities Class Action Investigation – ZTS WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zoetis Inc. (NYSE: ZTS) resulting from allegations that Zoetis may have issued materially misleading …

    Schreibe Deinen Kommentar

    Disclaimer